 CAMBRIDGE, Mass., April 10, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that clinical and translational data from the dose escalation portion of the Companys Phase 12 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be presented today at the American Association for Cancer Research AACR Virtual Annual Meeting in an e-poster titled Preliminary Safety and Efficacy of gavocabtagene autoleucel gavo-cel, TC-210, a T Cell Receptor Fusion Construct TRuC, in Patients with Treatment Refractory Mesothelin Overexpressing Solid Tumors. In addition, preclinical data from the Companys autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR. 